Pediatric Nephrology

, Volume 21, Issue 7, pp 1034–1036 | Cite as

Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir

  • Sabiha Hussain
  • Abeer Khayat
  • Asad Tolaymat
  • Mobeen H. Rathore
Brief Report

Abstract

Tenofovir-related tubule damage characterized by Fanconi syndrome, renal insufficiency and nephrogenic diabetes insipidus has been reported in the adult HIV-infected population. To our knowledge there has been no reported case of such complications in the pediatric population. We report the case of a 12-year-old perinatally HIV-infected African–American girl who developed nephrogenic diabetes insipidus, renal insufficiency and Fanconi-like syndrome while taking tenofovir (Viread) in combination with lopinavir–ritonavir (Kaletra) and didanosine (Videx).

Keywords

Fanconi syndrome Renal insufficiency Nephrogenic diabetes insipidus HIV Tenofovir 

References

  1. 1.
    Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, Legendre C, Martinez F, Molina JM (2003) Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 36:1070–1073PubMedCrossRefGoogle Scholar
  2. 2.
    Rollot F, Nazal E, Chauvelot-Moachon L, Kelaidi C, Daniel N, Saba M, Abad S, Blanche P (2003) Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir–ritonavir–didanosine. Clin Infect Dis 37:174–176CrossRefGoogle Scholar
  3. 3.
    Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, Leray H, Moachon L, Vincent D, Salmon-Ceron D (2004) Renal tubular dysfunction associated with tenofovir therapy. J Acquir Immune Defic Syndr 35:269–273PubMedCrossRefGoogle Scholar
  4. 4.
    Coca S, Perazella MA (2002) Rapid communication. Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 324:342–344PubMedCrossRefGoogle Scholar
  5. 5.
    Rifkin B, Parazella M (2004) Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 117:282–284PubMedCrossRefGoogle Scholar
  6. 6.
    US Food and Drug Administration (2001) FDA report: background package for NDA 21-356:Viread (tenofovir disoproxil fumarate)Google Scholar
  7. 7.
    Crowther MA, Callaghan W, Hodsman AB, Mackie ID (1993) Dideoxyinosine-associated nephrotoxicity. AIDS 7:131–132PubMedCrossRefGoogle Scholar
  8. 8.
    Fulco P, Kirian M (2003) Effect of tenofovir on didanosine absorption in patients with HIV. Ann Pharmacother 37:1325–1328CrossRefGoogle Scholar
  9. 9.
    Barrios A, Benayas-Garcia T, Gonzalez-Lahoz J, Soriano V (2004) Tenofovir- related nephrotoxicity in HIV-infected patients. AIDS 18:960–963PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2006

Authors and Affiliations

  • Sabiha Hussain
    • 1
  • Abeer Khayat
    • 1
  • Asad Tolaymat
    • 4
  • Mobeen H. Rathore
    • 1
    • 2
    • 3
  1. 1.Pediatric Infectious Diseases and ImmunologyUniversity of FloridaJacksonvilleUSA
  2. 2.Wolfson Children’s HospitalJacksonvilleUSA
  3. 3.JacksonvilleUSA
  4. 4.Department of PediatricsUniversity of FloridaJacksonvilleUSA

Personalised recommendations